Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke
Palà, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Pagola, Jorge (Hospital Universitari Vall d'Hebron)
Juega, Jesus (Hospital Universitari Vall d'Hebron)
Francisco Pascual, Jaume (Hospital Universitari Vall d'Hebron)
Penalba, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodriguez, Maite (Hospital Universitari Vall)
De Lera Alfonso, Mercedes (Hospital Clínico Universitario de Valladolid)
Arenillas, Juan F.. (Hospital Clínico Universitario de Valladolid)
Cabezas, Juan Antonio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Moniche, Francisco (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
de Torres, Reyes (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Pérez-Sánchez, Soledad (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
González-Alujas, Teresa (Hospital Universitari Vall d'Hebron)
Molina, Carlos A. (Hospital Universitari Vall d'Hebron)
Bustamante, Alejandro (Hospital Universitari Vall d'Hebron)
Montaner, Joan (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke. An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values. Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS. Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating.
Ajuts:	Instituto de Salud Carlos III PI15/02265 Instituto de Salud Carlos III PI18/0080 Instituto de Salud Carlos III RD16/0019/00021
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Atrial fibrillation ; Atrial cardiomyopathy ; Biomarkers ; Cryptogenic stroke ; Atrial function
Publicat a:	International journal of cardiology. Heart & vasculature, Vol. 39 (march 2022) , ISSN 2352-9067

DOI: 10.1016/j.ijcha.2022.100977
PMID: 35281755

7 p, 1018.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats